This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
MediciNova gets two cardio compounds from Meiji Seika Kaisha
01 Sep 2011
MediciNova has gained rights to two of Meiji Seika Kaisha's (infectious disease and neurological pharmaceuticals) small-molecule anti-thrombotic compounds. MN447 is in development for blood clot formation and MN462 for lysis; both have the potential for use in several thrombotic disorders. The worldwide license excludes Japan, Bangladesh, Brunei, Cambodia, the People's Republic of China, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?